Reagent kit and method for detecting digestive system tumor biological mark group by immunomic mass spectrometry
A technology of biomarkers and kits, applied in the field of disease detection, can solve the problem that disease markers cannot be detected at the same time
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0065] Example 1 Application of immune group mass spectrometry to detect variant expression of digestive system tumor biomarkers
[0066] (1) Experimental method
[0067] 1. Materials
[0068] 1. Specimen sources: A. Serum from 920 normal controls; B. Serum from 208 patients with gastric cancer; C. Serum from 226 patients with liver cancer; D. Serum from 182 patients with colorectal cancer.
[0069] 2. Quality control: A. Human standardized quality control serum B. Mass spectrometer laser energy regulation: Before each test, use the above-mentioned standardized quality control serum.
[0070] 3. The matrix contains the same amount of labeled antibodies: anti-FPA (fibrinopeptide A), anti-C3a (complement C3a), anti-ApoA-I (apolipoprotein A-I), anti-ApoA-II (apolipoprotein A-II) .
[0071] 2. Method
[0072] 1. Collection of samples: After the whole blood is collected, draw the serum and store it at -80°C; take out the serum sample in the refrigerator at -80°C, and put it on ...
Embodiment 2
[0085] Example 2 Sorting and Identification of Digestive System Tumor Biomarkers
[0086] The 1465±15Da, 8938±15Da, 28078±15Da, and 8707±15Da biomarkers were sequenced by MS / MS, post-source dissociation (PSD) and protein ladder sequencing. By breaking molecules into pieces, protein ladders can be generated. This gradient is then analyzed by mass spectrometry. Biomarkers identified as variantly expressed biomarker clusters:
[0087] Experimental results
[0088] (A) 1465±15Da: FPA-degAla (fibrinopeptide A with alanine removed from its amino terminal) sequence FPA fragment (1465.7Da, DSGEGDFLAEGGGVR)
[0089] (B) 8938±15Da: N-terminal of C3a-degArg (complement C3a whose C-terminal has removed arginine) sequence
[0090] Ser-Val-Gln-Leu-Thr-Glu-Lys-Arg-Met-Asp-Lys-Val-Gly-Lys-Tyr-Pro-Lys-Glu-Leu-Arg-Lys-Cys-Cys-Glu-Asp- Gly-Met-Arg-Glu-Asn-Pro-Met-Arg-Phe-Ser-Cys-Gln-Arg-Arg-Thr-Arg-Phe-lle-Ser-Leu-Gly-Glu-Ala-Cys-Lys- Lys-Val-Phe-Leu-Asp-Cys-Cys-Asn-Tyr-Ile-Thr-Glu-Leu-Arg-A...
Embodiment 3
[0103] Example 3 Preparation of mutated or modified biomarker antibodies
[0104] Synthesis of mutated or modified biomarkers: Synthesis of FPA-degAla, C3a-degArg, mutated ApoA-I, mutated ApoA-II. The synthetic mutated biomarkers were immunized into mice, and after the immune response appeared, B cells were isolated from peripheral blood. Single lymphocytes secreting the desired antibody were selected and isolated using a hemolytic plaque assay. Expand single cells to 1 x 10 7 More than one, the mRNA was extracted with the Quick mRNA Purification Kit. Using the extracted mRNA as a template, a cDNA strand is synthesized. Using this cDNA as a template, add the mouse antibody heavy chain variable region (V H ) universal primer, light chain variable region (V L ) universal primer, carry out polymerase chain reaction, obtain the amplified V H gene fragment and V L Gene fragment. The amplified products were identified and separated by 15g / L agarose gel electrophoresis. Reco...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com